A UK-based podcast active since 2012, produced by the BMJ Group and hosted by leading respiratory experts. It covers respiratory medicine research, guidelines, and interviews with global respiratory medicine leaders.
Interstitial lung disease treatment increasingly depends on inflammatory or fibrotic behaviour and evidence of progression. Antifibrotics slow rather than cure disease, while symptom control, representative trial recruitment, equitable diagnostic access and palliative care remain important alongside disease-modifying treatment.
Most participants in ETHOS and IMPACT already used inhaled corticosteroids, so the dual-therapy comparator withdrew established treatment. Reanalysis suggests the mortality difference may reflect withdrawal harm rather than proof that starting triple therapy reduces deaths.
Recurrent asthma or COPD exacerbations should not be reduced to a single biomarker. Blood eosinophils and FeNO need interpretation alongside symptoms, exacerbation subtype, smoking status, inhaled corticosteroid exposure, treatment changes and adherence uncertainty.
.svg)